POXEL
A biopharmaceutical company developing innovative treatments for serious chronic metabolic diseases.
About
POXEL SA is a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious chronic diseases with a metabolic pathophysiology. Their primary areas of focus include metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases. The company announced a new Tranche D PDR subscription agreement with IPF Partners on March 25, 2026. Teams look it up for Biotechnology, Pharmaceuticals, Healthcare.
Frequently asked
What does POXEL do?
POXEL is a Biotechnology company that offers Services. Teams look it up for Pharmaceuticals, Healthcare. It is based in Lyon, France and was founded in 2006. Public records show $4M in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has POXEL raised?
POXEL has raised a total of $4M in funding. The most recent round on record is Tranche D PDR Bond Issue.
Where is POXEL headquartered?
POXEL is headquartered in Lyon, France.
When was POXEL founded?
POXEL was founded in 2006.
What industry does POXEL operate in?
POXEL operates in Biotechnology, Pharmaceuticals, Healthcare.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.